Core Points - Teleflex Incorporated announced the retirement of Thomas E. Powell as Chief Financial Officer, effective April 1, 2025, with John R. Deren set to succeed him on April 2, 2025 [1][2] - Liam Kelly, Chairman and CEO, praised Powell's contributions, highlighting an 800 basis points increase in adjusted operating margin from 2012 to 2024, and emphasized the importance of succession planning for a smooth transition [2] - John Deren has over 30 years of financial management experience and has held various finance leadership roles within Teleflex since joining in 2013 [3] Company Overview - Teleflex is a global provider of medical technologies focused on improving health and quality of life, with a diverse portfolio in areas such as anesthesia, emergency medicine, interventional cardiology, and urology [4] - The company aims to be the most trusted partner in healthcare, driven by innovation and world-class products [4][5]

Core Viewpoint - Teleflex Incorporated plans to separate its Urology, Acute Care, and OEM businesses into a new independent publicly traded company, referred to as NewCo, through a tax-free distribution of newly issued shares to shareholders, expected to be completed by mid-2026 [1][5][13]. Group 1: Separation Details - The separation is driven by active portfolio management aimed at enhancing shareholder value and will allow RemainCo to focus on high-growth, hospital-centric end markets [2][5]. - RemainCo is projected to generate approximately $2.1 billion in revenue for 2024 and is expected to achieve constant currency revenue growth of over 6% post-separation [3][4]. - The transaction will streamline operations, reducing the number of manufacturing facilities from 19 to 7 for RemainCo, which will enhance operational efficiency and margin improvement opportunities [4][5]. Group 2: Business Focus Post-Separation - RemainCo will concentrate on Vascular Access, Interventional, and Surgical businesses, targeting high-acuity procedures primarily in hospital settings [3][5]. - NewCo will focus on Urology, Acute Care, and OEM markets, with an expected revenue of approximately $1.4 billion in 2024 and a mid-50% adjusted gross margin profile [10][11]. - NewCo anticipates low-single digit constant currency revenue growth, with potential for improvement as specific product lines recover and expand [11]. Group 3: Management and Financial Strategy - Liam Kelly will continue to lead RemainCo as its Chairman, President, and CEO [9]. - RemainCo aims for double-digit EPS growth in the first full year following the separation and plans to maintain a net leverage ratio below 3.0x through 2026 [7][8]. - NewCo will initiate an executive search for key management positions to ensure focused leadership in its specialized markets [12].

Core Viewpoint - Teleflex Incorporated has announced a definitive agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG for approximately €760 million, aiming to enhance its presence in the interventional cardiology and peripheral vascular market, which is estimated to be worth $10 billion [1][2]. Group 1: Acquisition Details - The acquisition is expected to close by the end of the third quarter of 2025, subject to customary closing conditions and regulatory approvals [1]. - The acquired business will expand Teleflex's portfolio to include a range of vascular intervention devices, with 75% of the acquired revenues coming from coronary interventions and 25% from peripheral procedures [2][3]. - Key products in the acquired portfolio include drug-coated balloons, drug-eluting stents, and various stent types for both coronary and peripheral interventions [2]. Group 2: Strategic Implications - The acquisition is anticipated to significantly enhance Teleflex's global presence in the cath lab and improve patient care through an expanded suite of innovative technologies [2]. - The integration of BIOTRONIK's products is expected to complement Teleflex's existing complex percutaneous coronary intervention (PCI) platform and diversify its geographic revenue mix, with 50% of the acquired revenues generated in EMEA [2][3]. - Teleflex plans to leverage its established education and clinical platforms to further enhance the offerings to cardiac and peripheral care specialists [4][5]. Group 3: Financial Outlook - The acquired products are projected to generate approximately €91 million in revenues in the fourth quarter of 2025, with expected constant currency revenue growth of 6% or better starting in 2026 [6][7]. - The transaction is expected to be approximately $0.10 accretive to Teleflex's adjusted earnings per share in the first year of ownership, with increasing accretion thereafter [8]. - Teleflex intends to finance the acquisition through a new term loan, revolving borrowings, and cash on hand, while also entering into foreign exchange derivative contracts to hedge against currency exposure [9][8].

WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG for an estimated cash payment on closing of approximately €760 million, less certain adjustments as provided in the purchase agreement including certain working capital not transferring and other customary adjustments. The acquisi ...

WAYNE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE:TFX), will be presenting at the Raymond James & Associates 46th Annual Institutional Investors Conference at the JW Marriott Grande Lakes, Orlando, FL, on Tuesday, March 4, 2025, at 3:25 p.m. (ET). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global pro ...

WAYNE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX), will be presenting at the Raymond James & Associates 46th Annual Institutional Investors Conference at the JW Marriott Grande Lakes, Orlando, FL, on Tuesday, March 4, 2025, at 3:25 p.m. (ET). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global pr ...

WAYNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 27, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beg ...

Including market leading Arrow™ CVCs and Arterial CathetersWAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been awarded a contract by Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement, effective January 1, 2025, covers the supply of Teleflex’s Central Venous Access Catheters and Arterial Catheters. Vizient provides solutions and services tha ...

WAYNE, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE:TFX), is scheduled to speak at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 14, 2025, at 5:15 p.m. (PT). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated ...

Teleflex’s (TFX) broad Vascular Access portfolio is poised to continue to win shares through its category leadership in Central Venous Catheters (CVC), midlines and new launches. The company’s expansion efforts into Asia bring promising long-term growth prospects. The Interventional arm is also driving solid growth through its key drivers, which is highly promising.  Meanwhile, the adverse impact of macroeconomic challenges and the competitive landscape remains a concern for Teleflex.In the past year, this ...